Predictors of cure in rifampicin-resistant tuberculosis in prison settings with low loss to follow-up
DESIGN: A total of 444 new and previously treated patients with pulmonary RR-TB who started treatment with second-line anti-tuberculosis drugs in the penitentiary system of Azerbaijan during the period 1 April 2007–28 February 2013 were retrospectively subjected to multivariate logistic regression analysis.
RESULTS: Of the 444 patients, 78.4% were cured. A higher number of effective bactericidal drugs in the regimen at months 7–12 and 13–18, normal chest X-ray and body mass index 18.5 kg/m2 at the treatment start significantly increased the chances of cure both in all cases (aOR 2.29, aOR 4.39, aOR 1.18, aOR 1.98 and aOR 1.97, respectively) and in retreatment cases (aOR 3.88, aOR 5.02, aOR 1.17, aOR 2.26 and aOR 1.90, respectively). There was no added benefit of using moxifloxacin (MFX) as compared to levofloxacin (LVX) in case of resistance to ofloxacin.
CONCLUSION: The use of a higher number of effective bactericidal drugs after month 6 of treatment for RR-TB was found to be the main factor associated with cure. No added benefit of using MFX instead of LVX was found. High cure rates can be achieved among vulnerable population groups such as prisoners if comprehensive TB control measures are in place to ensure low loss to follow-up.
Document Type: Research Article
Affiliations: 1: Main Medical Department, Ministry of Justice, Baku, Azerbaijan; Department of Pulmonary Medicine, University of Tartu, Tartu, Estonia 2: Main Medical Department, Ministry of Justice, Baku, Azerbaijan 3: Department of Communicable Disease Prevention and Control, Reykjavik Health Care Services, Reykjavik, Iceland 4: Department of Pulmonary Medicine, University of Tartu, Tartu, Estonia, Lung Clinic, Tartu University Hospital, Tartu, Estonia
Publication date: May 1, 2016
The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.
Certain IJTLD articles are selected for translation into French, Spanish, Chinese or Russian. They are available on the Union website
- Editorial Board
- Information for Authors
- Subscribe to this Title
- International Journal of Tuberculosis and Lung Disease
- Public Health Action
- Ingenta Connect is not responsible for the content or availability of external websites